Baird reiterates Mirum Pharmaceuticals stock rating on trial success
Baird reiterated an Outperform rating and $130 price target for Mirum Pharmaceuticals (MIRM) after positive Phase 3 trial results for maralixibat. The study met primary and secondary endpoints, with 50% of patients having biliary atresia. The company reported 44% revenue growth over the last year and is valued at $5.41 billion. Analysts revised earnings upwards, with price targets ranging from $118 to $195.
How this was made
The 30-second read
Why it matters
The trial data supports a label expansion, which could significantly increase the addressable market and drive revenue growth.
Market read
Positive trial results are a catalyst for biotech stocks, especially those targeting rare liver diseases.
What to watch
Potential competition from other bile‑acid therapies and the need for FDA filing timelines.
Background
Mirum Pharmaceuticals (NASDAQ:MIRM) announced its Phase 3 EXPAND basket study met primary and secondary endpoints, prompting analyst upgrades.
Ticker impact
Baird reiterated an Outperform rating and $130 price target after Mirum reported positive Phase 3 trial results.
upward pressure as investors price in potential label expansion and expanded patient pool
Phase 3 success is material for a biotech and analysts have raised targets, indicating strong market reaction.
Market effects
May lift other cholestatic disease biotech peers as trial success validates the therapeutic approach.
Primarily U.S. biotech sector; limited broader market effect.
Limited to investors tracking rare‑disease pipelines.
Counterpoint
If regulatory review stalls or safety concerns emerge, the rally could be short‑lived.
Key entities
- companyMirum Pharmaceuticals
Biotech firm developing treatments for cholestatic diseases.
- analyst_firmBaird
Equity research firm that reiterated an Outperform rating.
